• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

ASCO Audio Journal of Oncology in Advance – October 15th, 2006

0
  • by alexperjescuadmin
  • in AJO · ASCO · Oncology
  • — 14 Oct, 2006
Gordon McVie
Gordon McVie
Martine Piccart
Martine Piccart
Bella Kaufman
Bella Kaufman
Jean-Yves Douillard
Jean-Yves Douillard

ESMO Congress Reviewed

GORDON MCVIE, European Institute of Oncology, Milan
In Istanbul, Gordon McVie gave his opinion about the achievements of the 2006 European Society for Medical Oncology Congress. He added his comments regarding the news emerging from the Congress.

Trastuzumab in Early Breast Cancer: Latest Results; Gene Arrays to Avoid Chemotherapy?

REFERENCE: 31st European Society for Medical Oncology Congress, Istanbul, 29 September – 3 October 2006 Special Session
MARTINE PICCART, Jules Bordet Institute, Brussels
COMMENT: Gordon McVie

The latest evidence on how best to use trastuzumab in the treatment of early breast cancer was discussed at the ESMO conference by Martine Piccart from Brussels, who presented mature data from the HERA study of 5,000 patients conducted by the Breast International Group (BIG). The conference also heard about the group’s new “Microarray In Node-negative Disease may Avoid ChemoTherapy” (MINDACT) study, just beginning, in which 6,000 women are to be assessed by gene arrays to distinguish whether or not they require chemotherapy for their node negative disease.

Trastuzumab Plus Anastrozole: Better for Patients with Metastatic HER2+, ER+ Breast Cancer

REFERENCE: 31st European Society for Medical Oncology Congress, Istanbul, 29 September – 3 October 2006, Abstract LBA2
BELLA KAUFMAN, Chaim Sheba Medical Center, Tel-Hashomer, Israel
COMMENT: Gordon McVie

A combination of trastuzumab administered concurrently with anastrozole has extended progression-free survival in postmenopausal women with metastatic breast cancers expressing both the HER2 and estrogen receptors. Bella Kaufman from the Chaim Sheba Center in Israel discussed her findings with Peter Goodwin during the ESMO congress in Istanbul.

Adjuvant Cisplatin Plus Vinorelbine: Better Survival with Non Small-Cell Lung Cancer

REFERENCE: ESMO, Istanbul, 29 September – 3 October, 2006 Abstract: 710 o
JEAN-YVES DOUILLARD, Centre René Gauducheau, Nantes
COMMENT: Gordon McVie
A pooled analysis of adjuvant chemotherapy for lung cancer, the Lung Adjuvant Cisplatin Evaluation (LACE), has revealed that a combination of vinorelbine with cisplatin yields the best results, with the greatest improvements in survival, among patients diagnosed with stage III disease. During the Istanbul conference, Jean-Yves Douillard told Peter Goodwin about his conclusions.

Share

Tags: anastrozolebreastchemotherapycisplatinlungmetastatictrastuzumab

You may also like...

  • Big steps forward for advanced melanoma treatment Big steps forward for advanced melanoma treatment 10 Oct, 2013
  • HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation 15 Jan, 2014
  • Jean Charles PDL1 inhibitor brings better responses in smokers with refractory lung cancer 19 Nov, 2013
  • ASCO Audio Journal of Oncology in Advance – December 15th, 2006 – Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9-12, 2006 ASCO Audio Journal of Oncology in Advance – December 15th, 2006 – Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9-12, 2006 16 Dec, 2006

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty
  • Next story Audio Journal of Oncology in Advance – November 1st, 2006
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ribociclib Aids First-Line Endocrine Therapy in…
    • Polygenic Risk Scores Could Help Predict Second…
    • Ibrutinib: New Frontline Standard for Chronic…
    • Radiotherapy Cuts BRCA-Associated Contralateral…
    • Test Spares Extended Endocrine Therapy In Low-Risk…
  • Home
  • Oncology
  • AJO
  • ASCO Audio Journal of Oncology in Advance – October 15th, 2006

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.